Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 82 filers reported holding Y-MABS THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $413,426 | -49.5% | 34,224 | -32.2% | 0.00% | -66.7% |
| Q4 2021 | $819,000 | -46.3% | 50,503 | -5.4% | 0.01% | -40.0% |
| Q3 2021 | $1,524,000 | -21.4% | 53,409 | -6.9% | 0.02% | -11.8% |
| Q2 2021 | $1,940,000 | -1.0% | 57,386 | +12.5% | 0.02% | -41.4% |
| Q3 2020 | $1,959,000 | -16.4% | 51,029 | -5.9% | 0.03% | -6.5% |
| Q2 2020 | $2,343,000 | +31.9% | 54,239 | -20.4% | 0.03% | +121.4% |
| Q3 2019 | $1,777,000 | +8.6% | 68,175 | -4.8% | 0.01% | +16.7% |
| Q2 2019 | $1,637,000 | – | 71,575 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 191,176 | $2,757,000 | 9.37% |
| Sofinnova Investments, Inc. | 2,194,278 | $31,641,000 | 1.84% |
| MPM BioImpact LLC | 443,702 | $6,398,000 | 1.52% |
| Artal Group S.A. | 400,000 | $5,768,000 | 0.25% |
| Polar Capital Holdings Plc | 2,531,546 | $36,505,000 | 0.23% |
| ASHFORD CAPITAL MANAGEMENT INC | 101,970 | $1,470,000 | 0.22% |
| Lombard Odier Asset Management (Switzerland) SA | 168,795 | $2,434,000 | 0.21% |
| Soleus Capital Management, L.P. | 87,182 | $1,257,000 | 0.17% |
| Cormorant Asset Management, LP | 150,000 | $2,163,000 | 0.15% |
| Walleye Capital LLC | 437,344 | $6,307,000 | 0.12% |